Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.8K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A paradigm for studying the human impacts of disasters and extreme events using liminality.

The British journal of psychiatry : the journal of mental science·2026
Same author

Topical editorials, papers and commentaries: next 10 years.

BJPsych open·2026
Same author

Single-Ventricle Disease: Long-Term Outcomes and Global Morbidity in the Single Ventricle Reconstruction Trial.

Journal of the American College of Cardiology·2026
Same author

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Nature communications·2026
Same author

The Melanoma Pathology Report: What to Expect and How to Interpret It.

The Journal of dermatology·2025
Same author

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Research square·2025

Related Experiment Video

Updated: Jan 6, 2026

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.2K

Generation of TD50 values for carcinogenicity study data.

Andrew Thresher1, John Paul Gosling2, Richard Williams1

  • 1Lhasa Limited , Granary Wharf House , 2 Canal Wharf , Leeds , West Yorkshire LS11 5PS , UK .

Toxicology Research
|October 8, 2019
PubMed
Summary

This study presents a transparent method for calculating carcinogenic potency (TD50) values, crucial for chemical risk assessment and human safety thresholds. The new method, applied to existing data, shows high correlation but highlights discrepancies due to the outdated Carcinogenic Potency Data Base (CPDB) methodology.

More Related Videos

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.1K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.2K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.1K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.7K

Area of Science:

  • Toxicology
  • Chemical Risk Assessment
  • Carcinogenesis

Background:

  • Carcinogenic potency is vital for chemical risk assessment, informing metrics like threshold of toxicological concern (TTC), acceptable intake (AI), and permitted daily exposure (PDE).
  • The Carcinogenic Potency Data Base (CPDB) historically provided TD50 values but is no longer updated, necessitating a re-evaluation of its methodology.
  • Accurate carcinogenic potency data is essential for establishing safety thresholds and minimizing human exposure to potential carcinogens.

Purpose of the Study:

  • To develop a transparent and consistent methodology for calculating TD50 values from dose-response data.
  • To re-calculate TD50 values using the new methodology on data previously used by the CPDB.
  • To analyze the correlation between the newly calculated TD50 values and those from the CPDB, identifying sources of discrepancies.

Main Methods:

  • Development of a transparent methodology for TD50 calculation from experimental dose-response data.
  • Application of the developed methodology to the dataset utilized by the Carcinogenic Potency Data Base (CPDB).
  • Comparative analysis and correlation assessment between the TD50 values generated by the new methodology and the original CPDB values.

Main Results:

  • The newly developed methodology demonstrated a high overall correlation with the existing CPDB TD50 values.
  • Significant discrepancies were identified between the two sets of TD50 values.
  • Discrepancies were primarily attributed to the lack of methodological clarity in the CPDB and the inappropriate application of linear models for nonlinear dose-response data.

Conclusions:

  • The developed transparent methodology offers a reliable approach for calculating carcinogenic potency (TD50).
  • The findings underscore the limitations of the outdated CPDB methodology, particularly concerning its lack of transparency and statistical approach.
  • Re-evaluation and consistent application of robust methodologies are crucial for accurate human risk assessment and the establishment of reliable safety guidelines for chemical exposures.